RUNX2 and triple-negative breast carcinoma: Of note, Vishal and the colleagues further reviewed the potential dysfunction and regulation of RUNX2 in breast cancer mediated bone metastasis, yet the regulatory mechanism during the metastatic process and drug resistance in triple negative breast cancer was insufficiently disclosed (10).